These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 28168158)
1. Insights into the Binding of Cyclic RGD Peptidomimetics to α Guzzetti I; Civera M; Vasile F; Arosio D; Tringali C; Piarulli U; Gennari C; Pignataro L; Belvisi L; Potenza D ChemistryOpen; 2017 Feb; 6(1):128-136. PubMed ID: 28168158 [TBL] [Abstract][Full Text] [Related]
2. Cyclic RGD peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands. Marchini M; Mingozzi M; Colombo R; Guzzetti I; Belvisi L; Vasile F; Potenza D; Piarulli U; Arosio D; Gennari C Chemistry; 2012 May; 18(20):6195-207. PubMed ID: 22517378 [TBL] [Abstract][Full Text] [Related]
3. Investigating the Interaction of Cyclic RGD Peptidomimetics with α Civera M; Arosio D; Bonato F; Manzoni L; Pignataro L; Zanella S; Gennari C; Piarulli U; Belvisi L Cancers (Basel); 2017 Sep; 9(10):. PubMed ID: 28934103 [TBL] [Abstract][Full Text] [Related]
4. Cyclic RGD and Panzeri S; Arosio D; Gazzola S; Belvisi L; Civera M; Potenza D; Vasile F; Kemker I; Ertl T; Sewald N; Reiser O; Piarulli U Molecules; 2020 Dec; 25(24):. PubMed ID: 33339382 [TBL] [Abstract][Full Text] [Related]
5. Determination of the binding epitope of RGD-peptidomimetics to αvβ3 and α(IIb)β3 integrin-rich intact cells by NMR and computational studies. Guzzetti I; Civera M; Vasile F; Araldi EM; Belvisi L; Gennari C; Potenza D; Fanelli R; Piarulli U Org Biomol Chem; 2013 Jun; 11(23):3886-93. PubMed ID: 23657523 [TBL] [Abstract][Full Text] [Related]
6. Insight to the binding mode of triazole RGD-peptidomimetics to integrin-rich cancer cells by NMR and molecular modeling. Vasile F; Menchi G; Lenci E; Guarna A; Potenza D; Trabocchi A Bioorg Med Chem; 2016 Mar; 24(5):989-94. PubMed ID: 26818999 [TBL] [Abstract][Full Text] [Related]
7. Cyclic isoDGR and RGD peptidomimetics containing bifunctional diketopiperazine scaffolds are integrin antagonists. Panzeri S; Zanella S; Arosio D; Vahdati L; Dal Corso A; Pignataro L; Paolillo M; Schinelli S; Belvisi L; Gennari C; Piarulli U Chemistry; 2015 Apr; 21(16):6265-71. PubMed ID: 25761230 [TBL] [Abstract][Full Text] [Related]
8. Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity. Neubauer S; Rechenmacher F; Brimioulle R; Di Leva FS; Bochen A; Sobahi TR; Schottelius M; Novellino E; Mas-Moruno C; Marinelli L; Kessler H J Med Chem; 2014 Apr; 57(8):3410-7. PubMed ID: 24654918 [TBL] [Abstract][Full Text] [Related]
9. Determination of the binding specificity of an integral membrane protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin alphaIIbbeta3. Meinecke R; Meyer B J Med Chem; 2001 Sep; 44(19):3059-65. PubMed ID: 11543674 [TBL] [Abstract][Full Text] [Related]